SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

AcelRx Announces DSUVIA Added To US Department Of Defense's Joint Deployment Formulary

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative

· 09/14/2020 08:33

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the U.S. military's access to DSUVIA has been expanded with the addition of DSUVIA to the Department of Defense's Joint Deployment Formulary (JDF). The JDF is a core list of pharmaceutical products that are designated for deploying military units across all service branches.